Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 2/20 | 0.76 |
| ▸ | PDE5A | O76074 | 20/20 | 0.87 |
| ▸ | PDE1A | P54750 | 8/20 | 0.87 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.87 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.87 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.87 |
| ▸ | PDE6A | P16499 | 3/20 | 0.76 |
| ▸ | PDE2A | O00408 | 2/20 | 0.76 |
| ▸ | PDE6D | O43924 | 2/20 | 0.76 |
| ▸ | PDE9A | O76083 | 2/20 | 0.76 |
| ▸ | PDE6G | P18545 | 2/20 | 0.76 |
| ▸ | PDE4A | P27815 | 2/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.76 |
| ▸ | PDE6B | P35913 | 2/20 | 0.76 |
| ▸ | PDE6C | P51160 | 2/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537 | 0.93 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE4B | |
| Hydrochloric Acid SCHEMBL974638 | 0.93 | PDE5A (0.98) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823559 | 0.91 | PDE5A (0.94) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL8256987 | 0.90 | PDE5A (0.82) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12824080 | 0.88 | PDE5A (0.84) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823772 | 0.88 | PDE5A (0.84) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL974583 | 0.88 | PDE5A (0.89) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL14752434 | 0.88 | PDE5A (0.87) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL974895 | 0.88 | PDE5A (0.83) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL24418486 | 0.88 | PDE5A (0.90) | PDE5APDE1APDE1BPDE1CPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7696206-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20100016323-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20090221570-A1 | Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives for Treating Pulmonary Hypertension | BAYER HELTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20080113972-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-15 | — | — | US | disclosed |
| US-20080085897-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2008-04-10 | — | — | US | disclosed |
| US-7314871-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-01 | — | — | US | disclosed |
| US-20070299088-A1 | Novel Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives | BAYER HEALTHCARE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20060189615-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20050234022-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6930108-B2 | Use of 2-alkoxyphenol-substituted imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2005-08-16 | — | — | US | disclosed |
| US-6890922-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-05-10 | — | — | US | disclosed |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040235838-A1 | Use of 2-alkoxyphenol-substituted imidazotriazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040152700-A1 | Novel use of 2-phenyl-substituted imidazotriazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-08-05 | — | — | US | disclosed |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6566360-B1 | Administering 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position for therapy of hypertrophy of the prostate, incontinence or female sexual dysfunction in mammals | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-6362178-B1 | TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016323-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE2A, PDE3B | PDE3A 1/4885PDE5A 4/4885PDE1A 18/4885 |
| US-20070299088-A1 | Novel Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives | PDE5A, PDE2A, PDE3B | PDE3A 5/4885PDE5A 1/4885PDE1A 11/4885 |
| US-20080113972-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 25/4885 |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 25/4885 |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 25/4885 |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 25/4885 |
| US-20090221570-A1 | Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives for Treating Pulmonary Hypertension | PDE5A, PDE2A, PDE3B | PDE3A 4/4885PDE5A 1/4885PDE1A 20/4885 |
| US-20040235838-A1 | Use of 2-alkoxyphenol-substituted imidazotriazinones | PDE2A, PDE3B, PDE3A | PDE3A 3/4885PDE5A 6/4885PDE1A 143/4885 |
| US-20080085897-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 24/4885 |
| US-20060189615-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 25/4885 |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE5A 4/4885PDE1A 25/4885 |
| US-20040152700-A1 | Novel use of 2-phenyl-substituted imidazotriazinones | PDE7A, PDE4A, PDE5A | PDE3A 12/4885PDE5A 3/4885PDE1A 4/4885 |
| US-20050234022-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | PDE3B, PDE2A, PDE3A | PDE3A 3/4885PDE5A 5/4885PDE1A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.